Immuno-oncology
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”
Feature
How the microbiome influences the success of cancer therapy
Disruptions of the microbial system in the gut, as occur during antibiotic therapy, can have significant effects on a patient’s response to...
From the Journals
Immunotherapy stewardship could save tens of millions a year
“Why should we give a higher dose with the same efficacy when that dose will cost significantly more and has the potential to increase adverse...
Conference Coverage
CAR T-cell benefit in lenalidomide-refractory myeloma
“Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. Can this also be true for...
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Up-front pembro plus chemo boost survival in cervical cancer
Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers...
Conference Coverage
‘Huge step forward’ in advanced ovarian cancer
A preplanned interim analysis revealed that the addition of durvalumab and olaparib was associated with a 37% improvement of PFS, compared with...
Conference Coverage
SCLC: Bispecific antibody shows phase 1 promise
The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.
Conference Coverage
‘Exciting’ results for cancer vaccine plus pembro in melanoma
A new randomized study is the first to demonstrate improvement in recurrence-free survival in melanoma with an individualized neoantigen vaccine...
From the Journals
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
Conference Coverage
Study gives new insight into timing of combo treatment in metastatic NSCLC
Best outcomes came when immunotherapy followed radiotherapy by 1-12 months.